FDA Guidance on Conduct of Clinical Trials during COVID-19

FDAGCP
Written by ComplianceLogix

FDA guidance on the conduct of clinical trials of medical products during the coronavirus (COVID-19) Public Health Emergency, updated April 16, 2020. Read more at https://www.fda.gov/media/136238/download

ComplianceLogix
Previous

Best Practices for Remote Audits
Next

FDA Guidance on Providing Regulatory Submissions in Electronic and Non-Electronic Format